Current standard-of-care (SOC) therapy for breast cancer includes targeted therapies such
as endocrine therapy for estrogen receptor-alpha (ERα) positive; anti-HER2 monoclonal …

The epithelial to mesenchymal transition (EMT) is a cellular program that is involved in
embryonic development; wound healing, but also in tumorigenesis. Breast carcinoma (BC) …

Genetic screening identifies the atypical tetraspanin TM4SF1 as a strong mediator of
metastatic reactivation of breast cancer. Intriguingly, TM4SF1 couples the collagen receptor …

Dysregulation of fatty acid metabolism is recognized as a component of malignant
transformation in many different cancers, including breast; yet the potential for targeting this …

Abstract The 17β-estradiol (E2)/estrogen receptor alpha (ERα) signaling pathway is one of
the most important pathways in hormone-dependent breast cancer. E2 plays pivotal roles in …

Significance: Epithelial–mesenchymal transition (EMT) is emerging as a driving force in
tumor progression, enabling cancer cells to evade their “homeland” and to colonize remote …

Resistance to anti-estrogen therapy is an unsolved clinical challenge in successfully treating
ER+ breast cancer patients. Recent studies have demonstrated the role of non-genetic (ie …

The epithelial to mesenchymal transition (EMT) has been proposed to contribute to the
metastatic spread of breast cancer cells. EMT-promoting transcription factors determine a …

Background Developing an understanding of the biochemistry of aging in both sexes is
critical for managing disease throughout the lifespan. Lipidomic associations with age and …

In epithelial-to-mesenchymal transition (EMT) epithelial cancer cells achieve mesenchymal
features, essentially helping them to metastasize. There is some evidence that EMT could be …